customisable counter
 
Trovagene, news, press room, events, IR, investor relations, services, San Diego, lab, laboratory, operations, clinical, applications, alien, prenatal, testing, metastatic, pregnancy, diagnosism, pathogens, tumor, therapies, analysis, trans-renal, genetic, information, kidney, circulating, technology, license, licensing opportunities, science, platform, research, development, R&D, pipeline, TROV, DNA, RNA, molecular, diagnostics, urine, test, detection, cancer, medicine, nucleic acid, infection, revolution, disease, personalized medicine, non-invasive, CLIA, markers

Trovagene, INC.  |  TROV.PK

Trovagene, news, press room, events, IR, investor relations, services, San Diego, lab, laboratory, operations, clinical, applications, alien, prenatal, testing, metastatic, pregnancy, diagnosism, pathogens, tumor, therapies, analysis, trans-renal, genetic, information, kidney, circulating, technology, license, licensing opportunities, science, platform, research, development, R&D, pipeline, TROV, DNA, RNA, molecular, diagnostics, urine, test, detection, cancer, medicine, nucleic acid, infection, revolution, disease, personalized medicine, non-invasive, CLIA, markers

About Us

Services

Technology

Disease Areas

News & Events

Contact Us

 

Media Resources


Trovagene LOGO

» download high-res PNG

» download vector EPS

 

NEWS & EVENTS


May 10, 2012

Trovagene, Inc., Announces Issuance of European Patent for Detection of Pathogenic Infections

Read more »

Download PDF »


May 2, 2012

Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine.

Read more »

Download PDF »


May 1, 2012

Dr. Carlo Croce joins Trovagene as Scientific Consultant and Member of the Company’s SAB

Read more »

Download PDF »


Apr 30, 2012

Trovagene Announces Validation Program for Trans-Renal K-RAS Mutation Detection in Pancreatic Cancer

Read more »

Download PDF »


Apr 25, 2012

Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations

Read more »

Download PDF »

Feb 27, 2012

Trovagene Expands Business Development Efforts Through a Partnership with Leomics Associates, Inc.

Read more »

Download PDF »


Feb 14, 2012

Trovagene appoints Charlie Rodi, Ph.D., as Chief Technology Officer

Read more »

Download PDF »


Feb 10, 2012

Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer

Read more »

Download PDF »


Feb 8, 2012

Trovagene Closes Acquisition of CLIA Laboratory Assets

Read more »

Download PDF »


Jan 17, 2012

Trovagene Presentation [8k filing]: Introduction to Trovagene, Antonius Schuh, CEO

8k filing »

Download PDF »


Jan 6, 2012

Trovagene Acquires CLIA - Certified Laboratory

Read more »


Jan 3, 2012

Trovagene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia

Read more »


2011


Dec 7, 2011

Antonius Schuh, Ph.D. Joins Trovagene, Inc. As Chief Executive Officer

Read more »


Sept 7, 2011

Trovagene, Inc., Announces Worldwide Exclusive Licensing of Assay for Hairy Cell Leukemia

Read more »


August 10, 2011

Trovagene, Inc. Confirms It Has Regained Its Rights to Transrenal Technology for Non-Invasive Prenatal Testing and Cancer

Read more »

 

  1. ‣News & Events

  2. ‣Investors

Trovagene, news, press room, events, IR, investor relations, services, San Diego, lab, laboratory, operations, clinical, applications, alien, prenatal, testing, metastatic, pregnancy, diagnosism, pathogens, tumor, therapies, analysis, trans-renal, genetic, information, kidney, circulating, technology, license, licensing opportunities, science, platform, research, development, R&D, pipeline, TROV, DNA, RNA, molecular, diagnostics, urine, test, detection, cancer, medicine, nucleic acid, infection, revolution, disease, personalized medicine, non-invasive, CLIA, markers

Science Backgrounder

Trovagene, news, press room, events, IR, investor relations, services, San Diego, lab, laboratory, operations, clinical, applications, alien, prenatal, testing, metastatic, pregnancy, diagnosism, pathogens, tumor, therapies, analysis, trans-renal, genetic, information, kidney, circulating, technology, license, licensing opportunities, science, platform, research, development, R&D, pipeline, TROV, DNA, RNA, molecular, diagnostics, urine, test, detection, cancer, medicine, nucleic acid, infection, revolution, disease, personalized medicine, non-invasive, CLIA, markers

We have compiled a literature review to summarize the state of science in the field of circulating nucleic acid detection and the promise their detection holds, particularly in the management of cancer patients.

» download The Detection of Transrenal Nucleic Acids for Patient Management PDF

 

Trovagene, Inc. (TROV.PK)


Trovagene is currently traded on the Pink Sheets as TROV.PK.  The company is currently working on the requirements necessary for re-listing.

For additional information please contact:

ir@trovagene.com



Downloads


April, 2012

PRESENTATION: Introduction to Trovagene, Inc., Antonius Schuh, CEO

» download PDF